202 related articles for article (PubMed ID: 28181369)
1. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy.
Coppola A; D'Ausilio A; Aiello A; Amoresano S; Toumi M; Mathew P; Tagliaferri A;
Haemophilia; 2017 May; 23(3):422-429. PubMed ID: 28181369
[TBL] [Abstract][Full Text] [Related]
2. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.
Tagliaferri A; Feola G; Molinari AC; Santoro C; Rivolta GF; Cultrera DB; Gagliano F; Zanon E; Mancuso ME; Valdré L; Mameli L; Amoresano S; Mathew P; Coppola A;
Thromb Haemost; 2015 Jul; 114(1):35-45. PubMed ID: 25855376
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
[TBL] [Abstract][Full Text] [Related]
5. COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS, COMPARED WITH ON-DEMAND TREATMENT, FOR PATIENTS WITH SEVERE HEMOPHILIA TYPE A IN COLOMBIA.
Castro Jaramillo HE; Moreno Viscaya M; Mejia AE
Int J Technol Assess Health Care; 2016 Jan; 32(5):337-347. PubMed ID: 27919309
[TBL] [Abstract][Full Text] [Related]
6. Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A.
Miners A
Haemophilia; 2009 Jul; 15(4):881-7. PubMed ID: 19473422
[TBL] [Abstract][Full Text] [Related]
7. Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment.
Farrugia A; Cassar J; Kimber MC; Bansal M; Fischer K; Auserswald G; O'Mahony B; Tolley K; Noone D; Balboni S
Haemophilia; 2013 Jul; 19(4):e228-38. PubMed ID: 23534877
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia.
Miners AH; Sabin CA; Tolley KH; Lee CA
Pharmacoeconomics; 2002; 20(11):759-74. PubMed ID: 12201795
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy and safety of 12-month low-dose factor VIII tertiary prophylaxis vs on-demand treatment in severe haemophilia A children.
Chozie NA; Primacakti F; Gatot D; Setiabudhy RD; Tulaar ABM; Prasetyo M
Haemophilia; 2019 Jul; 25(4):633-639. PubMed ID: 31044491
[TBL] [Abstract][Full Text] [Related]
10. Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective.
Lorenzoni V; Triulzi I; Turchetti G
BMC Health Serv Res; 2018 Aug; 18(1):596. PubMed ID: 30071878
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of emicizumab prophylaxis in patients with haemophilia A in India.
Seth T; John MJ; Chakrabarti P; Shanmukhaiah C; Verma SP; Radhakrishnan N; Dolai TK
Haemophilia; 2024 Mar; 30(2):426-436. PubMed ID: 38147060
[TBL] [Abstract][Full Text] [Related]
12. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
Tunis SL; Willis WD; Foos V
Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of low-dose prophylaxis versus on-demand treatment for moderate-to-severe hemophilia A in India.
Seth T; Garg K; Mandal PK; Datta A; Verma S; Hanagavadi S; Thota UR
Hematology; 2023 Dec; 28(1):2277497. PubMed ID: 37933875
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea.
Lee H; Cho H; Han JW; Kim AY; Park S; Lee M; Cho S; Baik D; Kang HY
Haemophilia; 2021 Jan; 27(1):e12-e21. PubMed ID: 32894895
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of health-related quality of life of boys with severe haemophilia A in China: comparing on-demand to prophylaxis treatment.
Wu R; Sun J; Xiao J; Liu Y; Xue F; Wang H; Tang L; Zhao Y; Li K; Yang R; Hu Y; Luke KH; Poon MC; Blanchette VS; Usuba K; Young NL
Haemophilia; 2017 May; 23(3):430-436. PubMed ID: 28345299
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of haemophilia treatment: a cross-national assessment.
Lippert B; Berger K; Berntorp E; Giangrande P; van den Berg M; Schramm W; Siebert U;
Blood Coagul Fibrinolysis; 2005 Oct; 16(7):477-85. PubMed ID: 16175006
[TBL] [Abstract][Full Text] [Related]
18. Haemophilia A: pharmacoeconomic review of prophylaxis treatment versus on-demand.
Unim B; Veneziano MA; Boccia A; Ricciardi W; La Torre G
ScientificWorldJournal; 2015; 2015():596164. PubMed ID: 25685844
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors.
Cortesi PA; Castaman G; Trifirò G; Creazzola SS; Improta G; Mazzaglia G; Molinari AC; Mantovani LG
Thromb Haemost; 2020 Feb; 120(2):216-228. PubMed ID: 31887777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
